PAA 4.26% 22.5¢ pharmaust limited

Ann: Extension Study Begins, Analysis Suggests Survival Benefit, page-198

  1. 2,375 Posts.
    lightbulb Created with Sketch. 1471
    Yes,, the incredible, continuing survival of the patients - wuthout the need for assisted swallowing and respiration and is one reason why I'm bemused by people carrying over as if there is a risk that MPL will not find a medical use. Each new day that continues is a small miracle. It's stuff like this, along with all the wonderful biomarker results, the visible suppression of the MND inflammations, and the statements made by Professor Susan Maher way back in the first half of last year, that got me to switch over from my usual cautious statements up to the end of 2022, to increasing excitement about the MND trial, and of course why Buckland like boilerplate statements about clinical trial risk are a absolutely laughable, along with the backup that we know now from years of research and this last human trial that MPL has a future anyway as a safe and easy to use mTOR inhibitor for something or other anyway.
    Last edited by Lastly: 22/03/24
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
22.5¢
Change
-0.010(4.26%)
Mkt cap ! $89.08M
Open High Low Value Volume
23.5¢ 23.5¢ 22.0¢ $170.5K 749.0K

Buyers (Bids)

No. Vol. Price($)
2 34313 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.5¢ 24444 2
View Market Depth
Last trade - 16.10pm 14/06/2024 (20 minute delay) ?
Last
22.5¢
  Change
-0.010 ( 6.25 %)
Open High Low Volume
23.0¢ 23.0¢ 22.0¢ 246904
Last updated 15.57pm 14/06/2024 ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.